Premium
Gene polymorphism affecting α1‐antichymotrypsin and interleukin‐1 plasma levels increases Alzheimer's disease risk
Author(s) -
Licastro Federico,
Pedrini Steve,
Ferri Cinzia,
Casadei Valeria,
Govoni Marzia,
Pession Annalisa,
Sciacca Francesca Luisa,
Veglia Fabrizio,
Ani Giorgio,
Bonafè Massimiliano,
Olivieri Fabiola,
Franceschi Claudio,
Grimaldi Luigi Maria Edoardo
Publication year - 2000
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/1531-8249(200009)48:3<388::aid-ana16>3.0.co;2-g
Subject(s) - odds ratio , genotype , disease , polymorphism (computer science) , confidence interval , medicine , alzheimer's disease , immunology , concomitant , interleukin 1β , interleukin , gastroenterology , endocrinology , gene , biology , genetics , cytokine
Plasma levels of α1‐antichymotrypsin (ACT) and inter‐leukin‐1β (IL‐1β) were increased in patients with probable Alzheimer's disease (AD). A common polymorphism within ACT and IL‐1β genes affected plasma levels of ACT or IL‐1β, and AD patients with the ACT T,T or IL‐1β T,T genotype showed the highest levels of plasma ACT or IL‐1β, respectively. The concomitant presence of the ACT T,T and IL‐1β T,T genotypes increased the risk of AD (odds ratio: 5.606, confidence interval: 1.654–18.996) and decreased the age at onset of the disease. Ann Neurol 2000;48:388–391